{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:13Z","timestamp":1791821113918,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016156","name":"U.S. Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["W81XWH-16-1-0385"],"award-info":[{"award-number":["W81XWH-16-1-0385"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ymthe.2020.12.037","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T17:01:56Z","timestamp":1610211716000},"page":"1541-1556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway"],"prefix":"10.1016","volume":"29","author":[{"given":"Yongsheng","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika N.","family":"Kodumudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Ramamoorthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Wiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Pilon-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Zi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo L.B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.12.037_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.037_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexmp.2009.05.001","article-title":"The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies","volume":"87","author":"Freudenberg","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","article-title":"Breast cancer brain metastases: biology and new clinical perspectives","volume":"18","author":"Witzel","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2020.12.037_bib5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2020.12.037_bib6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.CCR-11-2701","article-title":"Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2020.12.037_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13058-015-0584-1","article-title":"Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer","volume":"17","author":"Datta","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2020.12.037_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2015.5482","article-title":"Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring","volume":"2","author":"Datta","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib10","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.18632\/oncotarget.10298","article-title":"T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells","volume":"10","author":"Namjoshi","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.12.037_bib11","doi-asserted-by":"crossref","first-page":"23058","DOI":"10.18632\/oncotarget.25208","article-title":"Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies","volume":"9","author":"Rosemblit","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.12.037_bib12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.celrep.2015.08.044","article-title":"Disabling of the erbB pathway followed by IFN-\u03b3 modifies phenotype and enhances genotoxic eradication of breast tumors","volume":"12","author":"Nagai","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2020.12.037_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.gde.2004.12.011","article-title":"Hsp90 and Cdc37\u2014a chaperone cancer conspiracy","volume":"15","author":"Pearl","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.037_bib14","first-page":"21","article-title":"Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it","volume":"10","author":"Luque-Cabal","year":"2016","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib15","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","article-title":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","volume":"7","author":"de Melo Gagliato","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2020.12.037_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-020-0153-3","article-title":"Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond","volume":"6","author":"Costa","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ymthe.2020.12.037_bib17","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.037_bib18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.037_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.037_bib20","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2019.01939","article-title":"Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T\u00a0cells in mediating the response","volume":"10","author":"Kodumudi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib21","doi-asserted-by":"crossref","first-page":"7626","DOI":"10.4049\/jimmunol.177.11.7626","article-title":"Distinct and non-overlapping T\u00a0cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB\/c mice","volume":"177","author":"Rolla","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-3-030-20301-6_10","article-title":"Current updates on trastuzumab resistance in HER2 overexpressing breast cancers","volume":"1152","author":"Ahmad","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2019.05.001","article-title":"Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives","volume":"139","author":"Vernieri","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib25","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.12.037_bib26","first-page":"4892","article-title":"Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2","volume":"61","author":"Cuello","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.12.037_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2020.12.037_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2020.12.037_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2020.12.037_bib33","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","article-title":"DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice","volume":"165","author":"Rovero","year":"2000","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2020.12.037_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.12.037_bib35","doi-asserted-by":"crossref","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","article-title":"ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays","volume":"9","author":"Guzm\u00e1n","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.12.037_bib36","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1073\/pnas.1322412111","article-title":"E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells","volume":"111","author":"Samant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.037_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","article-title":"Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper\u2014Excel-based tool using pair-wise correlations","volume":"26","author":"Pfaffl","year":"2004","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ymthe.2020.12.037_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1593\/neo.07112","article-title":"Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles","volume":"9","author":"Rhodes","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2020.12.037_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","article-title":"ONCOMINE: a cancer microarray database and integrated data-mining platform","volume":"6","author":"Rhodes","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2020.12.037_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2020.12.037_bib41","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2020.12.037_bib42","doi-asserted-by":"crossref","first-page":"bas060","DOI":"10.1093\/database\/bas060","article-title":"bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses","volume":"2013","author":"J\u00e9z\u00e9quel","year":"2013","journal-title":"Database (Oxford)"},{"key":"10.1016\/j.ymthe.2020.12.037_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10549-011-1457-7","article-title":"bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer","volume":"131","author":"J\u00e9z\u00e9quel","year":"2012","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620307309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620307309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:07:53Z","timestamp":1782490073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620307309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1525001620307309"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}